Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of vorinostat (Zolinza) and azacitidine
(Vidaza) when combined with gemtuzumab ozogamicin (GO) at different dose levels. These drugs
increase the effect of GO against leukemia cells in the test tube, but we don't know yet
whether they also increase the anti-leukemia effect of GO in people.